Skip to main content

Immunocore Holdings Limited (IMCR)

NASDAQ: IMCR · IEX Real-Time Price · USD
34.76 -1.05 (-2.93%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap1.52B
Revenue (ttm)28.08M
Net Income (ttm)n/a
Shares Out43.79M
EPS (ttm)-4.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume44,753
Open35.80
Previous Close35.81
Day's Range34.54 - 35.81
52-Week Range27.77 - 61.99
Betan/a
Analystsn/a
Price Target52.00 (+49.6%)
Est. Earnings DateNov 10, 2021

About IMCR

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cance...

IndustryBiotechnology
IPO DateFeb 5, 2021
Employees291
Stock ExchangeNASDAQ
Ticker SymbolIMCR
Full Company Profile

Financial Performance

In 2020, Immunocore's revenue was 30.11 million, an increase of 17.32% compared to the previous year's 25.67 million. Losses were -74.09 million, -28.71% less than in 2019.

Financial numbers in millions GBPFinancial Statements

News

Immunocore to present at upcoming investor conferences

PRESS RELEASE

2 weeks ago - GlobeNewsWire

Immunocore's Eye Cancer Candidate Under Priority Review In US, Europe

The U.S. and European Union regulators have accepted for review Immunocore Holdings Plc's (NASDAQ: IMCR) marketing applications seeking approval for tebentafusp for uveal melanoma (eye cancer). Related:...

1 month ago - Benzinga

Immunocore to present at upcoming investor conferences

P RESS RELEASE

3 months ago - GlobeNewsWire

Immunocore Reports First Quarter 2021 Financial Results

PRESS RELEASE

4 months ago - GlobeNewsWire

3 Recent IPO Stocks That Could Be Bigger Winners Than Coinbase

Coinbase's IPO was spectacular. But these stocks with recent IPOs might have better long-term prospects.

Other symbols:AFRMRBLX
5 months ago - The Motley Fool

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

6 months ago - GlobeNewsWire

Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary

6 months ago - GlobeNewsWire

Newly Listed Immunocore's Tebentafusp Receives Breakthrough Therapy Tag For Eye Cancer

The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresectable or met...

7 months ago - Benzinga